第一选择
伊维菌素
:
体重≥15 kg 的儿童和成人：200 µg/㎏，顿服
第二选择
阿苯达唑
:
1-2 岁儿童：200 mg，口服，每天一次，连服 3 天；≥2 岁的儿童和成人：400 mg，口服，每日一次，连服 3 天
CLM 是典型的自限性疾病，即使不进行特定治疗，最终也会痊愈，且无后遗症（通常在 2-8 周内）。但是，给予驱虫药治疗，通常可以使症状在 1 周内迅速消失。
首选治疗方法是伊维菌素，顿服，通常可治愈。[20]Blackwell V, Vega-Lopez F. Cutaneous larva migrans: clinical features and management of 44 cases presenting in the returning traveller. Br J Dermatol. 2001;145:434-437.http://www.ncbi.nlm.nih.gov/pubmed/11531833?tool=bestpractice.com[28]Bouchaud O, Houzé S, Schiemann R, et al. Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clin Infect Dis. 2000;31:493-498. [Erratum in: Clin Infect Dis. 2001;32:523.]http://cid.oxfordjournals.org/content/31/2/493.fullhttp://www.ncbi.nlm.nih.gov/pubmed/10987711?tool=bestpractice.com治疗与 CLM 有关的毛囊炎，效果不理想。[43]Vanhaecke C, Perignon A, Monsel G, et al. The efficacy of single dose ivermectin in the treatment of hookworm related cutaneous larva migrans varies depending on the clinical presentation. J Eur Acad Dermatol Venereol. 2014;28:655-657.http://www.ncbi.nlm.nih.gov/pubmed/23368818?tool=bestpractice.com由于临床资料有限，体重＜15 kg 的儿童应避免使用伊维菌素。
口服阿苯达唑可替代伊维菌素治疗CLM，尽管一次顿服阿苯达唑的治愈率偏低。临床治疗：伊维菌素顿服治疗 CLM 的治愈率是77% 至 100%，阿苯达唑顿服治疗 CLM 的治愈率是46%，P = 0.017。差异具有统计学意义。[28]Bouchaud O, Houzé S, Schiemann R, et al. Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clin Infect Dis. 2000;31:493-498. [Erratum in: Clin Infect Dis. 2001;32:523.]http://cid.oxfordjournals.org/content/31/2/493.fullhttp://www.ncbi.nlm.nih.gov/pubmed/10987711?tool=bestpractice.com[44]Caumes E, Carriere J, Guermonprez G, et al. Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis. 1995;20:542-548.http://www.ncbi.nlm.nih.gov/pubmed/7756473?tool=bestpractice.com[45]Van den Enden E, Stevens A, Van Gompel A. Treatment of cutaneous larva migrans. N Engl J Med. 1998;339:1246-1247.http://www.ncbi.nlm.nih.gov/pubmed/9786758?tool=bestpractice.com[46]Caumes E, Carriere J, Datry A, et al. A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg. 1993;49:641-644.http://www.ncbi.nlm.nih.gov/pubmed/8250105?tool=bestpractice.com受试者＜200名的随机对照临床试验（RCT）、受试者＞200名且方法学存在缺陷的随机对照临床试验（RCT）、方法学存在缺陷的系统评价或者高质量的观察性（队列）研究。用药3 天至 5 天后的治愈率与伊维菌素相当，在 77% 至 100% 之间。[3]Davies HD, Sakuls P, Keystone JS. Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol. 1993;129:588-591.http://www.ncbi.nlm.nih.gov/pubmed/8481019?tool=bestpractice.com[20]Blackwell V, Vega-Lopez F. Cutaneous larva migrans: clinical features and management of 44 cases presenting in the returning traveller. Br J Dermatol. 2001;145:434-437.http://www.ncbi.nlm.nih.gov/pubmed/11531833?tool=bestpractice.com[47]Jones SK, Reynolds NJ, Oliwiecki S, et al. Oral albendazole for the treatment of cutaneous larva migrans. Br J Dermatol. 1990;122:99-101.http://www.ncbi.nlm.nih.gov/pubmed/2297509?tool=bestpractice.com由于临床资料有限，年龄 ＜1 岁的儿童应避免使用阿苯达唑。
鉴于驱虫药物治疗效果理想，不建议对 CLM 患者采用局部皮质类固醇和抗组胺药治疗。此外，没有资料显示瘙痒与组胺有关。
